Results of multi-center non-randomized, non-comparative trial of efficacy and safety of levofloxacin in moderate communityacquired pneumonia
Abstract
The article shows results of Russian multi-center trial of efficacy and safety of levofloxacin in moderate community-acquired pneumonia (CAP) patients took place from October, 2001, to November, 2002, at Moscow, Nizhny Novgorod, Samara, Ekaterinburg, Chelyabinsk, Tyumen and Irkutsk. The trial involved 77 patients (37 females and 40 males with the average age of 40.8±14.4 yrs) admitted to a hospital with the CAP. Levofloxacin was given in a standard dose of 500 meg once a day, the average length of the treatment was 9.2 days. The clinical efficacy of the single-therapy with levofloxacin was 98.7%. Adverse effects were noted in 4 cases (nausea was in 4 patients and headache was in 1 patient). The therapy was abolished in 1 case due to the adverse effects.
About the Authors
A. I. Sinopalnikov
Кафедра пульмонологии с курсом фтизиатрии Государственного института усовершенствования врачей МО РФ
Russian Federation
Russian Federation
Yu. G. Belotserkovskaya
Кафедра пульмонологии с курсом фтизиатрии Государственного института усовершенствования врачей МО РФ
Russian Federation
Russian Federation
A. G. Romanovskikh
Кафедра пульмонологии с курсом фтизиатрии Государственного института усовершенствования врачей МО РФ
Russian Federation
Russian Federation
References
1. Зайратьянц О.В. Анализ смертности, летальности, числа аутопсий и качества клинической диагностики в Москве за последнее десятилетие (1991-2000 гг.). Арх. пат. 2002; 3 (прил.): 1-64.
2. Страчунский Л.C., Козлов P.C., Кречикова О.И. и др. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-I). Клин. Микробиол. и антимикроб. Химиотер. 2002; 4 (3): 267-277.
3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.
4. Amsden G.W., Amankw a K. Pneumococcal resistance: The treatment challenge. Ann Pharmacother. 2001; 35 (4): 480-488.
5. Bartlett J.G. et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2000; 31 (2): 347-382.
6. Bartlett J.G. Respiratory tract infections. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
7. Brown P.O., Lerner S.A. Community-acquired pneumonia. Lancet 1998; 352: 1295-1302.
8. Carbon C., Ariza H., Rabie W.J. et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mildto-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 1999; 5: 724-732.
9. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contact: United States. Morbid. Mortal. Wkly Rep. 1997; 46: 556.
10. Davis R., Bryson H. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.
11. File T.M , Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41 (9): 1965-1972.
12. Gleason P.P., Kapoor W.N., Lave J.R. et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. J.A.M.A. 1997; 278: 32-39.
13. Marrie T.J. Community-acquired pneumonia. Clin. Infect. Dis. 1994; 18: 501-515.
14. Mommeja-Marin H., Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? Drugs 1999; 57( 6): 851-853.
15. Ruis-G onzalez A., Falguera М ., Nogues A. et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community- acquired pneumonia. Am. J. Med. 1999; 106: 385-390.
Review
For citations:
Sinopalnikov A.I., Belotserkovskaya Yu.G., Romanovskikh A.G. Results of multi-center non-randomized, non-comparative trial of efficacy and safety of levofloxacin in moderate communityacquired pneumonia. PULMONOLOGIYA. 2003;(4):83-89. (In Russ.)
Views:
183
Email this article 